QALSODY (tofersen) injection

QALSODY is a prescription medicine used to treat amyotrophic lateral sclerosis (ALS). FDA approved tofersen (brand name QALSODY) is not (yet) registered or available in India but on request Indian patient can buy QALSODY at the lowest price.

QALSODY (tofersen) injection Price Delhi India
QALSODY (tofersen) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

QALSODY (tofersen) injection

Tofersen is indicated to treat people with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).

QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY.

Tofersen, sold under the brand name Qalsody, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). Tofersen is an antisense oligonucleotide that targets the production of superoxide dismutase 1, an enzyme whose mutant form is commonly associated with amyotrophic lateral sclerosis. Tofersen was approved for medical use in the United States in April 2023, and in the European Union in May 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

The most common side effects include fatigue, arthralgia (joint pain), increased cerebrospinal (brain and spinal cord) fluid white blood cells, and myalgia (muscle pain).

QALSODY (tofersen) injection, for intrathecal use Initial U.S. Approval: 2023
—————-
Current Indication: Treat amyotrophic lateral sclerosis (ALS)
—————-
Marketed By: Biogen a
—————-
Approval Date: : 2023
—————-
Active ingredients: tofersen
—————-

Injection: 100 mg/15 mL (6.7 mg/mL) solution in a single-dose vial

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.